Official statement of B. Braun Philippines

Official statement of B. Braun Philippines

Several statements were made about B. Braun Avitum Philippines, Inc. (B. Braun Avitum) at the Philippine Senate Hearing on 4th August 2020 and 11th August 2020. The Company would like to respond to these statements by presenting the relevant facts.

As a medical technology company with a global history of 180 years and having served the Filipino people for 34 years, B. Braun holds itself strictly to the highest standards of integrity in all its business dealings. To B. Braun, Compliance is more than simply complying with laws and legal requirements. It also embraces the ethical values of integrity, fairness, and sustainability. In each and every one of our business transactions, we adhere to the most stringent standards of integrity and professionalism.

During the on-going pandemic, the funds made available through the Interim Reimbursement Mechanism (IRM) to support the operations of all Philippine healthcare institutions (HCIs) have enabled B. Braun Avitum to continue to provide quality renal services to dialysis patients who require regular treatment. Such treatment must not be interrupted despite the coronavirus situation, as our patients’ lives will be compromised. Together with all other HCIs who have and are receiving IRM funds, B. Braun Avitum is deeply appreciative of the IRM funds received from PhilHealth.

Our company was registered with the Securities and Exchange Commission (SEC) on 11th December 1985 as B. Braun Medical Supplies, Inc., whereas, B. Braun Avitum, a wholly-owned subsidiary of B. Braun Medical Supplies, Inc., was originally incorporated as Philippine Renal Care, Inc. on 24th January 2002 (Company Registration Number A200201223) and later renamed as B. Braun Avitum Philippines, Inc.

B. Braun Avitum owns and manages 25 dialysis centers across Luzon to treat patients requiring renal care.

We are one with the government in its quest for transparency and good governance, and will extend full cooperation in this endeavor.

For more information, please contact:

Ma. Cecilia Victoria Cannon
Corporate Communications